BRPI0607323B8 - compositions, uses of polypeptides and antibodies, as well as kits for detecting antibody that specifically binds to a polypeptide - Google Patents

compositions, uses of polypeptides and antibodies, as well as kits for detecting antibody that specifically binds to a polypeptide

Info

Publication number
BRPI0607323B8
BRPI0607323B8 BRPI0607323A BRPI0607323A BRPI0607323B8 BR PI0607323 B8 BRPI0607323 B8 BR PI0607323B8 BR PI0607323 A BRPI0607323 A BR PI0607323A BR PI0607323 A BRPI0607323 A BR PI0607323A BR PI0607323 B8 BRPI0607323 B8 BR PI0607323B8
Authority
BR
Brazil
Prior art keywords
polypeptides
compositions
kits
polypeptide
specifically binds
Prior art date
Application number
BRPI0607323A
Other languages
Portuguese (pt)
Inventor
E Straub Darren
A Emery Daryll
Wonderling Laura
L Herron Olson Lisa
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Publication of BRPI0607323A2 publication Critical patent/BRPI0607323A2/en
Publication of BRPI0607323B1 publication Critical patent/BRPI0607323B1/en
Publication of BRPI0607323B8 publication Critical patent/BRPI0607323B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1285—Gram-positive bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composições e uso de polipeptídeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo. a presente invenção fornece polipeptideos isolados que podem ser isolados partindo de um staphylococcus spp. são também fornecidas pela presente invenção composições que incluem um ou mais dos polipeptideos e métodos para a produção e métodos para a utilização dos polipeptideos.compositions and use of polypeptides and kits for detecting antibody that specifically binds to a polypeptide. the present invention provides isolated polypeptides which can be isolated starting from a staphylococcus spp. Also provided by the present invention are compositions which include one or more of the polypeptides and methods for producing and methods for using the polypeptides.

BRPI0607323A 2005-02-14 2006-02-14 compositions, uses of polypeptides and antibodies, as well as kits for detecting antibody that specifically binds to a polypeptide BRPI0607323B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65284305P 2005-02-14 2005-02-14
US60/652,843 2005-02-14
PCT/US2006/005058 WO2006088803A2 (en) 2005-02-14 2006-02-14 Polypeptides from staphylococcus aureus and methods of use

Publications (3)

Publication Number Publication Date
BRPI0607323A2 BRPI0607323A2 (en) 2009-09-01
BRPI0607323B1 BRPI0607323B1 (en) 2020-12-22
BRPI0607323B8 true BRPI0607323B8 (en) 2021-05-25

Family

ID=36694403

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607323A BRPI0607323B8 (en) 2005-02-14 2006-02-14 compositions, uses of polypeptides and antibodies, as well as kits for detecting antibody that specifically binds to a polypeptide

Country Status (12)

Country Link
US (13) US8007811B2 (en)
EP (1) EP1853306B1 (en)
JP (3) JP2008532935A (en)
CN (2) CN101119744B (en)
AU (1) AU2006214534B2 (en)
BR (1) BRPI0607323B8 (en)
CA (1) CA2597263C (en)
DK (1) DK1853306T3 (en)
ES (1) ES2586125T3 (en)
MX (1) MX2007009828A (en)
NZ (4) NZ597997A (en)
WO (1) WO2006088803A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
EP0749321B1 (en) * 1994-02-09 2007-01-24 Epitopix LLC Active immunization using a siderophore receptor protein
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
ES2395022T3 (en) * 2003-09-19 2013-02-07 Epitopix, Llc Campylobacter polypeptides and their methods of use
EP1853306B1 (en) 2005-02-14 2016-06-15 Epitopix, LLC Polypeptides from staphylococcus aureus and methods of use
WO2007100580A2 (en) * 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
JP5564249B2 (en) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in cancer
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
EP2411046B1 (en) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
CN106146664B (en) 2011-03-31 2021-09-07 Adc治疗股份有限公司 Antibodies against kidney-associated antigen 1 and antigen-binding fragments thereof
CA3115623A1 (en) 2012-01-09 2013-07-18 Adc Therapeutics Sa Method for treating breast cancer
US9169477B2 (en) 2012-01-27 2015-10-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for immunization against bacteria expressing a carbapenemase
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
MX2018000395A (en) * 2015-07-10 2018-05-23 Epitopix Llc Proteins and immunizing compositions containing klebsiella proteins and methods of use.
WO2017024038A1 (en) * 2015-08-03 2017-02-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Solar concentrator for a tower-mounted central receiver
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
TWI733412B (en) * 2020-04-13 2021-07-11 華邦電子股份有限公司 Semiconductor device with air gap and method of fabricating the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
EP0749321B1 (en) * 1994-02-09 2007-01-24 Epitopix LLC Active immunization using a siderophore receptor protein
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6403337B1 (en) * 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
CA2255669A1 (en) * 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
KR20020097200A (en) 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 Identification of essential genes in prokaryotes
AT410173B (en) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh ANTIQUE COMPOSITION
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
AT410798B (en) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
WO2003020875A2 (en) 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
WO2004013166A2 (en) 2002-07-26 2004-02-12 Intercell Ag S. aureus antigene
US6947260B2 (en) * 2002-11-18 2005-09-20 Hitachi Global Storage Technologies Netherlands B.V. System and method of damping vibration on coil supports in high performance disk drives with rotary actuators
ES2395022T3 (en) 2003-09-19 2013-02-07 Epitopix, Llc Campylobacter polypeptides and their methods of use
WO2005103073A2 (en) * 2004-04-27 2005-11-03 Intercell Ag Td antigens
WO2006021893A2 (en) 2004-08-26 2006-03-02 The University Of Western Ontario Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
KR20070085457A (en) 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 Iron, surface-determining factors, IsdA, IsdX, and IsdC based vaccines, compositions and methods regulated by iron of Staphylococcus aureus
EP1853306B1 (en) 2005-02-14 2016-06-15 Epitopix, LLC Polypeptides from staphylococcus aureus and methods of use
EP2411046B1 (en) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use

Also Published As

Publication number Publication date
NZ589238A (en) 2012-02-24
US20130288952A1 (en) 2013-10-31
US8007811B2 (en) 2011-08-30
US8709436B2 (en) 2014-04-29
US20070087011A1 (en) 2007-04-19
CN103143006B (en) 2016-08-03
US20150023969A1 (en) 2015-01-22
US20100221253A1 (en) 2010-09-02
US20080200650A1 (en) 2008-08-21
HK1117746A1 (en) 2009-01-23
US9266944B2 (en) 2016-02-23
CA2597263A1 (en) 2006-08-24
US8709760B2 (en) 2014-04-29
US20060233824A1 (en) 2006-10-19
WO2006088803A3 (en) 2006-12-21
US20170182146A1 (en) 2017-06-29
US9623076B2 (en) 2017-04-18
BRPI0607323B1 (en) 2020-12-22
EP1853306A2 (en) 2007-11-14
CA2597263C (en) 2017-01-17
CN101119744A (en) 2008-02-06
EP1853306B1 (en) 2016-06-15
WO2006088803A2 (en) 2006-08-24
AU2006214534B2 (en) 2012-07-19
JP2013053155A (en) 2013-03-21
ES2586125T3 (en) 2016-10-11
NZ597997A (en) 2013-10-25
NZ613923A (en) 2015-02-27
US20160068590A9 (en) 2016-03-10
AU2006214534A1 (en) 2006-08-24
US20140005360A1 (en) 2014-01-02
DK1853306T3 (en) 2016-09-05
BRPI0607323A2 (en) 2009-09-01
JP2008532935A (en) 2008-08-21
CN101119744B (en) 2013-03-13
CN103143006A (en) 2013-06-12
US20150210757A1 (en) 2015-07-30
US8007803B2 (en) 2011-08-30
US8961979B2 (en) 2015-02-24
JP6100826B2 (en) 2017-03-22
JP2015155457A (en) 2015-08-27
MX2007009828A (en) 2007-09-27
NZ560612A (en) 2011-01-28
US20160158312A1 (en) 2016-06-09
US20130287813A1 (en) 2013-10-31
US8025885B2 (en) 2011-09-27
US20130280300A1 (en) 2013-10-24
US20120164685A1 (en) 2012-06-28
US9981028B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
CY1123518T1 (en) HUMAN ENANTI-TAU ANTIBODIES
CY1124802T1 (en) SCLEROSTEIN BINDING FACTORS
CY1122210T1 (en) HUMAN ANTI-SOD1 ANTIBODIES
CY1120951T1 (en) HUMAN ANTIBODIES ENANTI-TAU
DE602006006200D1 (en) ANTIBODY AGAINST 25-HYDROXYVITAMINE D
BRPI0607323A2 (en) compositions and use of polypeptides and kits for detecting antibody that specifically binds to a polypeptide
AR061246A1 (en) ANTI-DILL4 ANTIBODIES AND METHODS THAT USE THEM
BR112012023010A8 (en) ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO CD37, IMMUNOCONJUGATE COMPRISING THE SAME, USE OF THE SAID ANTIBODY, FRAGMENT AND IMMUNOCONJUGATE, COMPOSITION COMPRISING THE SAME, KIT, ISOLATED CELL, AS WELL AS IN VITRO METHOD TO INHIBIT GROWTH MENT OF A CELL THAT EXPRESSES CD37
BRPI0812878B8 (en) isolated antibody or functional part of it, vector, method for producing an antibody or a functional part of it, for producing an antibody producing cell and for producing an antibody capable of specifically binding to rsv, composition, and, use of an antibody or functional part of it or a composition or vector
BR112019000970A2 (en) multispecific antigen binding proteins and methods of use thereof
EA201201533A1 (en) PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
TR201901841T4 (en) Constant dosing of each antibody.
CR20160206A (en) Compositions and methods for antibodies that target C5 complement protein
MX2018008680A (en) Tdp-43 specific binding molecules.
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
BRPI0607486B8 (en) 1243 humanized antibody against hla-dr present in hladr+ cells, pharmaceutical composition, kit and use of said antibodies.
BRPI0812488A2 (en) HUMANIZED AND CHEMICAL ANTI-BODIES ANTIBODIES MEDIATION OF CANCER CELL, USES OF THE SAME, CONNECTION TESTS, METHODS, COMPOSITIONS AND TEST KIT
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
AR057237A1 (en) METHODS AND COMPOSITIONS TO ACT ON POLYUBIQUITINE
MX365387B (en) Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
CO6270369A2 (en) NEW SPECIFIC ANTIBODIES OF BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC OR DRUG AGENTS
PT1791571E (en) RADIOFLUORED PEPTIDES
NZ583894A (en) Antibodies that bind to a non atp binding p2x7 receptor
DK1987357T3 (en) Polypeptides recognized by anti-Trichinella antibodies and uses thereof
EA201000258A1 (en) NEW HERBICIDES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2866 DE 09-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.